Evidence map›Paper›PMID 30348467›Full record

ArticleJournal of hepatology2019

Reply to: "Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment".

George N Ioannou

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Journal of hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

George N IoannouDivision of Gastroenterology, Department of Medicine Veterans Affairs Puget Sound Healthcare System and University of Washington, Seattle, WA, United States; Research and Development, Veterans Affairs Puget Sound Healthcare System, Seattle, WA, United States. Electronic address: georgei@medicine.washington.edu.

Funding

Does Screening for HCC in Cirrhotic Patients Reduce HCC-related Mortality?R01CA196692 · NCI · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · PI IOANNOU, GEORGE, WEISS, NOEL S · 2015 to 2018
$985k
NCI NIH HHS R01 CA196692
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antiviral AgentsCarcinoma, HepatocellularHepatitis CHepatitis C, ChronicLiver NeoplasmsHumansAntiviral Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.